GAMMA Investing’s Enliven Therapeutics ELVN Stock Holding History

GAMMA Investing’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20.5K	Buy	447 +219	+96%	+$11.9K	﹤0.01%	2934
2026 Q2	$11.6K	Buy	228 +6	+3%	+$255	﹤0.01%	3134
2026 Q1	$8.7K	Buy	222 +32	+17%	+$887	﹤0.01%	3143
2025 Q4	$2.93K	Sell	190 -12	-6%	-$239	﹤0.01%	3491
2025 Q3	$4.13K	Buy	202 +1	+0.5%	+$20	﹤0.01%	3246
2025 Q2	$4.03K	Buy	201 +63	+46%	+$1.19K	﹤0.01%	3200
2025 Q1	$2.72K	Buy	138 +52	+60%	+$1.12K	﹤0.01%	3316
2024 Q4	$1.94K	Buy	86 +20	+30%	+$518	﹤0.01%	3231
2024 Q3	$1.69K	Buy	66 +17	+35%	+$394	﹤0.01%	3117
2024 Q2	$1.15K	Sell	49 -4	-8%	-$84	﹤0.01%	3025
2024 Q1	$932	Buy	53 +16	+43%	+$245	﹤0.01%	2958
2023 Q4	$581	Buy	+37	New	+$453	﹤0.01%	2928

Other funds holding ELVN

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing's ELVN Position: Q3 2026 in Review

GAMMA Investing increased its Enliven Therapeutics (ELVN) stake by 96% in Q3 2026, buying an estimated $11.9K and bringing the position to 447 shares worth $20.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2934.

GAMMA Investing first reported a position in ELVN in Q4 2023 and has held it in 12 quarters since. 4 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

GAMMA Investing held 447 shares of Enliven Therapeutics worth $20.5K as of Q3 2026.
GAMMA Investing bought 219 Enliven Therapeutics shares in Q3 2026, an estimated $11.9K.
Enliven Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2934 holding.
GAMMA Investing first reported a position in Enliven Therapeutics in Q4 2023 and has held it in 12 quarters since.
4 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.